Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study.

van Vollenhoven RF, Stohl W, Furie RA, Fox NL, Groark JG, Bass D, Kurtinecz M, Pobiner BF, Eastman WJ, Gonzalez-Rivera T, Gordon D.

Lupus Sci Med. 2018 Nov 26;5(1):e000288. doi: 10.1136/lupus-2018-000288. eCollection 2018.

2.

A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.

Doria A, Bass D, Schwarting A, Hammer A, Gordon D, Scheinberg M, Fox NL, Groark J, Stohl W, Kleoudis C, Roth D.

Lupus. 2018 Aug;27(9):1489-1498. doi: 10.1177/0961203318777634. Epub 2018 May 28.

3.

Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.

Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D.

Arthritis Rheumatol. 2018 Aug;70(8):1256-1264. doi: 10.1002/art.40511. Epub 2018 Jun 15.

4.

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.

Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D.

Arthritis Rheumatol. 2017 May;69(5):1016-1027. doi: 10.1002/art.40049. Epub 2017 Apr 7.

5.

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
.

Sheikh SZ, Hammer AE, Fox NL, Groark J, Struemper H, Roth D, Gordon D.

Int J Clin Pharmacol Ther. 2016 Nov;54(11):914-922.

6.

Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects.

Struemper H, Murtaugh T, Gilbert J, Barton ME, Fire J, Groark J, Fox NL, Roth D, Gordon D.

Clin Pharmacol Drug Dev. 2016 May;5(3):208-15. doi: 10.1002/cpdd.219. Epub 2015 Dec 4.

7.

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.

Ciuleanu T, Bazin I, Lungulescu D, Miron L, Bondarenko I, Deptala A, Rodriguez-Torres M, Giantonio B, Fox NL, Wissel P, Egger J, Ding M, Kalyani RN, Humphreys R, Gribbin M, Sun W.

Ann Oncol. 2016 Apr;27(4):680-7. doi: 10.1093/annonc/mdw004. Epub 2016 Jan 22.

PMID:
26802147
8.

Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

von Pawel J, Harvey JH, Spigel DR, Dediu M, Reck M, Cebotaru CL, Humphreys RC, Gribbin MJ, Fox NL, Camidge DR.

Clin Lung Cancer. 2014 May;15(3):188-196.e2. doi: 10.1016/j.cllc.2013.12.005. Epub 2013 Dec 27.

PMID:
24560012
9.

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.

Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM, Klein J, Halpern W, Miceli R, Kumm E, Fox NL, Czuczman MS.

Br J Cancer. 2010 Dec 7;103(12):1783-7. doi: 10.1038/sj.bjc.6605987. Epub 2010 Nov 16.

10.

Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.

Fox NL, Humphreys R, Luster TA, Klein J, Gallant G.

Expert Opin Biol Ther. 2010 Jan;10(1):1-18. doi: 10.1517/14712590903319656. Review.

PMID:
19857186
11.

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S.

Clin Cancer Res. 2009 Sep 1;15(17):5584-90. doi: 10.1158/1078-0432.CCR-09-0996. Epub 2009 Aug 18. Erratum in: Clin Cancer Res. 2009 Nov 1;15(21):6744.

12.

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.

Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG.

J Clin Oncol. 2009 Sep 10;27(26):4413-21. doi: 10.1200/JCO.2008.21.7422. Epub 2009 Aug 3.

PMID:
19652058
13.

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.

Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, Ullrich SJ, Fisher GA, Tolcher AW.

Ann Oncol. 2010 Feb;21(2):376-81. doi: 10.1093/annonc/mdp292. Epub 2009 Jul 24.

14.

A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.

Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, Iacobucci A, MacLean M, Lo L, Fox NL, Oza AM.

Clin Cancer Res. 2008 Jun 1;14(11):3450-5. doi: 10.1158/1078-0432.CCR-07-1416.

15.

Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.

Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, Barrett M, Judson I, Kaye S, Fox NL, Halpern W, Corey A, Calvert H, de Bono J.

Clin Cancer Res. 2007 Oct 15;13(20):6187-94.

16.

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, Cohen RB.

J Clin Oncol. 2007 Apr 10;25(11):1390-5. Erratum in: J Clin Oncol. 2007 Oct 10;25(29):4701.

PMID:
17416859
17.

Quality of life after coronary artery bypass graft: results from the POST CABG Trial.

Fox NL, Hoogwerf BJ, Czajkowski S, Lindquist R, Dupuis G, Herd JA, Campeau L, Hickey A, Barton FB, Terrin ML; POST CABG Study Investigators.

Chest. 2004 Aug;126(2):487-95.

PMID:
15302735
18.

Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.

Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G, Pehrsson K, Verheugt FW, Meyer J, Betriu A, Califf RM, Li X, Fox NL; ASSENT-2 Investigators. Assessment of the Safety and Efficacy of a New Thrombolytic.

Eur Heart J. 2001 Dec;22(24):2253-61.

PMID:
11728145
19.

The general concepts of an equivalence trial, applied to ASSENT-2, a large-scale mortality study comparing two fibrinolytic agents in acute myocardial infarction.

Lesaffre E, Bluhmki E, Wang-Clow F, Berioli S, Danays T, Fox NL, Van de Werf F.

Eur Heart J. 2001 Jun;22(11):898-902. No abstract available.

PMID:
11428813
20.

The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment.

Walenga JM, Hoppensteadt D, Pifarré R, Fox NL, Forman S, Hunninghake DB, Campeau L, Herd JA, Hoogwerf BJ, Hickey A, Probstfield JL, Terrin ML.

J Thromb Thrombolysis. 2001 Apr;11(2):143-9.

PMID:
11406729
21.

Determination of a weight-adjusted dose of TNK-tissue plasminogen activator.

Wang-Clow F, Fox NL, Cannon CP, Gibson CM, Berioli S, Bluhmki E, Danays T, Braunwald E, Van De Werf F, Stump DC.

Am Heart J. 2001 Jan;141(1):33-40.

PMID:
11136484
22.

Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction.

Modi NB, Fox NL, Clow FW, Tanswell P, Cannon CP, Van de Werf F, Braunwald E.

J Clin Pharmacol. 2000 May;40(5):508-15.

PMID:
10806604
23.

Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators.

Gibson CM, Cannon CP, Murphy SA, Adgey AA, Schweiger MJ, Sequeira RF, Grollier G, Fox NL, Berioli S, Weaver WD, Van de Werf F, Braunwald E.

Am J Cardiol. 1999 Nov 1;84(9):976-80.

PMID:
10569649
24.

Correlation of CT findings with clinical evaluations in 261 patients with symptomatic bronchiectasis.

Lynch DA, Newell J, Hale V, Dyer D, Corkery K, Fox NL, Gerend P, Fick R.

AJR Am J Roentgenol. 1999 Jul;173(1):53-8.

PMID:
10397099
25.

Hemostatic effects of 1 mg daily warfarin on post CABG patients. Post CABG Studies Investigators.

Walenga JM, Hoppensteadt D, Pifarré R, Cressman MD, Hunninghake DB, Fox NL, Terrin ML, Probstfield JL.

J Thromb Thrombolysis. 1999 Jun;7(3):313-8.

PMID:
10373714
26.

Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.

Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, Bluhmki E, Sarelin H, Wang-Clow F, Fox NL, Braunwald E.

Am Heart J. 1999 May;137(5):786-91.

PMID:
10220625
27.

TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.

Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E.

Circulation. 1997 Jan 21;95(2):351-6.

PMID:
9008448
28.

Prenatal exposure to tobacco: II. Effects on cognitive functioning at age three.

Sexton M, Fox NL, Hebel JR.

Int J Epidemiol. 1990 Mar;19(1):72-7.

PMID:
2351527
29.

Prenatal exposure to tobacco: I. Effects on physical growth at age three.

Fox NL, Sexton M, Hebel JR.

Int J Epidemiol. 1990 Mar;19(1):66-71.

PMID:
2351526
30.

The reliability of self-reports of smoking and alcohol consumption by pregnant women.

Fox NL, Sexton M, Hebel JR, Thompson B.

Addict Behav. 1989;14(2):187-95.

PMID:
2658483
31.

Dose-response of birth weight to various measures of maternal smoking during pregnancy.

Hebel JR, Fox NL, Sexton M.

J Clin Epidemiol. 1988;41(5):483-9.

PMID:
3367179
32.
33.

Developmental screening using parent report.

Kenny TJ, Hebel JR, Sexton MJ, Fox NL.

J Dev Behav Pediatr. 1987 Feb;8(1):8-11.

PMID:
2434530
34.

Occupational allergy to laboratory animals: an epidemiologic study.

Bland SM, Levine MS, Wilson PD, Fox NL, Rivera JC.

J Occup Med. 1986 Nov;28(11):1151-7.

PMID:
3491199
35.

Inhibition of esterase activity and an undercounting of circulating monocytes in a population of production workers.

Levine MS, Fox NL, Thompson B, Taylor W, Darlington AC, Van der Hoeden J, Emmett EA, Rutten W.

J Occup Med. 1986 Mar;28(3):207-11.

PMID:
3701467
36.

Hallelujah! Common sense at last!. Interview by Ethel Gillette.

Fox NL.

J Nurs Care. 1982 Jul;15(7):6. No abstract available.

PMID:
6922189
37.

Sound off! Sex in the nursing home? For Lord's sake, why not?

Fox NL.

RN. 1980 Oct;43(10):95-100. No abstract available.

PMID:
6902980
38.

A kitten in the care plan?

Fox NL.

J Pract Nurs. 1979 Oct;29(10):30. No abstract available.

PMID:
258674
39.

How to help meet your patients' spiritual needs.

Fox NL.

J Pract Nurs. 1979 Apr;29(4):32-3. No abstract available.

PMID:
257004
40.

Nursing intervention: holiday happiness...all year 'round.

Fox NL.

J Pract Nurs. 1978 Dec;28(12):20-2. No abstract available.

PMID:
251580
41.

Steroid production from 17alpha-hydroxypregnenolone and dehydroepiandrosterone by human granulosa cells in vitro.

Fowler RE, Fox NL, Edwards RG, Steptoe PC.

J Reprod Fertil. 1978 Sep;54(1):109-17.

PMID:
152353
42.

Steroidogenesis by cultured granulosa cells aspirated from human follicles using pregnenolone and androgens as precursors.

Fowler RE, Fox NL, Edwards RG, Walters DE, Steptoe PC.

J Endocrinol. 1978 May;77(2):171-83.

PMID:
660038
43.

Rx: range-of-motion--for the funnybone.

Fox NL.

J Pract Nurs. 1978 Feb;28(2):13. 23. No abstract available.

PMID:
244534
44.

To make meaningful their days.

Fox NL.

J Pract Nurs. 1978 Feb;28(2):11. No abstract available.

PMID:
244533
45.

Visible vs. invisible nursing.

Fox NL.

J Pract Nurs. 1978 Jan;28(1):32. No abstract available.

PMID:
244530
46.

A call to arms.

Fox NL.

J Pract Nurs. 1977 Jun;27(6):17, 31. No abstract available.

PMID:
585724
47.

The slap-stick chart.

Fox NL.

J Pract Nurs. 1976 Feb;26(2):32-3. No abstract available.

PMID:
1042168
48.

Aftermath of stroke: triumph or tragedy?

Fox NL.

J Pract Nurs. 1975 Apr;25(4):22-4. No abstract available.

PMID:
1038470
49.

A good birth, a good life, why not a good death?

Fox NL.

J Pract Nurs. 1974 Oct;24(10):19-20. No abstract available.

PMID:
4497542
50.

Making geriatric nursing creative.

Fox NL.

J Pract Nurs. 1973 Sep;23(9):20-1. No abstract available.

PMID:
4489934

Supplemental Content

Support Center